Ganga Pharma.
Ticker > Company >

Ganga Pharma. share price

Ganga Pharmaceuticals Ltd.

BSE: 539680 SECTOR: Pharmaceuticals & Drugs  11.43 K   17   0

14.60
0 0
BSE: 03 Sep 4:00 PM

Price Summary

Today's High

₹ 14.6

Today's Low

₹ 14.6

52 Week High

₹ 19.2

52 Week Low

₹ 9.25

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 8.63 Cr.

Enterprise Value

₹ 9.96 Cr.

No. of Shares

0.59 Cr.

P/E

110.69

P/B

1.09

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  13.43

CASH

₹ 0.03 Cr.

DEBT

₹ 1.36 Cr.

Promoter Holding

50.91 %

EPS (TTM)

₹  0.13

Sales Growth

5.78%

ROE

0.78 %

ROCE

3.16%

Profit Growth

18.6 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year5.78%
3 Year4.84%
5 Year-4.04%

Profit Growth

1 Year18.6%
3 Year31.82%
5 Year-24.27%

ROE%

1 Year0.78%
3 Year0.74%
5 Year1.24%

ROCE %

1 Year3.16%
3 Year3.31%
5 Year4.1%

Debt/Equity

0.2112

Price to Cash Flow

-6.83

Interest Cover Ratio

1.3428

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 50.91 0.00
Mar 2025 56.02 0.00
Sep 2024 56.02 0.00
Mar 2024 56.02 0.00
Dec 2023 56.02 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy liquidity position with current ratio of 4.8101.
  • The company has a high promoter holding of 50.91%.

 Limitations

  • The company has shown a poor revenue growth of 4.83615226672036% for the Past 3 years.
  • Company has a poor ROE of 0.737075615745622% over the past 3 years.
  • Company has a poor ROCE of 3.31461583648928% over the past 3 years
  • Company has negative cash flow from operations of -1.263962.
  • The company has a low EBITDA margin of 3.58559103783751% over the past 5 years.
  • The company is trading at a high EV/EBITDA of 31.2193.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2018
Net Sales 1.95
Total Expenditure 1.73
Operating Profit 0.21
Other Income 0.07
Interest 0.14
Depreciation 0.04
Exceptional Items 0
Profit Before Tax 0.11
Tax 0.03
Profit After Tax 0.09
Adjusted EPS (Rs) 0.21

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 3.08 2.37 2.49 2.59 2.74
Total Expenditure 2.69 2.34 2.45 2.58 2.68
Operating Profit 0.39 0.03 0.04 0 0.06
Other Income 0.17 0.25 0.26 0.3 0.24
Interest 0.24 0.2 0.19 0.19 0.18
Depreciation 0.05 0.05 0.05 0.06 0.05
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.26 0.04 0.05 0.05 0.06
Tax 0.07 0.02 0.01 0.01 0.02
Net Profit 0.19 0.02 0.04 0.04 0.05
Adjusted EPS (Rs.) 0.46 0.05 0.09 0.1 0.1

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 4.06 4.06 4.06 4.06 4.84
Total Reserves 1.29 1.31 1.35 1.39 2.22
Borrowings 0.59 0.67 0.89 0.63 0.39
Other N/C liabilities 0.01 0.01 0.01 0 0
Current liabilities 1.62 1.61 1.69 1.89 1.2
Total Liabilities 7.57 7.66 8 7.98 8.65
Assets
Net Block 0.76 0.72 0.68 0.64 0.61
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0.09 0.09 0.09 0.09 0.09
Loans & Advances 2.3 2.26 2.32 2.11 1.44
Other N/C Assets 0 0 0 0 0.76
Current Assets 4.42 4.59 4.91 5.15 5.75
Total Assets 7.57 7.66 8 7.98 8.65
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 0.26 0.04 0.05 0.05 0.06
Adjustment 0.11 -0.02 -0.01 -0.06 -0.01
Changes in Assets & Liabilities -0.61 -0.18 -0.23 -0.02 -1.3
Tax Paid -0.06 -0.01 -0.01 -0.02 -0.02
Operating Cash Flow -0.31 -0.18 -0.21 -0.04 -1.26
Investing Cash Flow 0.37 0.28 0.19 0.49 0.13
Financing Cash Flow -0.29 -0.1 0.03 -0.44 1.14
Net Cash Flow -0.22 0 0.01 0.01 0

Corporate Actions

Investors Details

PARTICULARS Dec 2023% Mar 2024% Sep 2024% Mar 2025% Jun 2025%
promoters 56.02 56.02 56.02 56.02 50.91
amit shukla 1.58 1.58 1.58 1.58 1.29
anagh bharat sharma 5.38 5.38 5.38 5.38 6.09
ankita amit shukla 0.83 0.83 0.83 0.83 0.68
bharat brijmohan sharma h... 3.93 3.93 3.93 3.93 3.21
brijmohan sharma huf 7.23 7.23 7.23 7.23 5.91
sharma bharat b 30.12 30.12 30.12 30.12 24.64
srijna sharma 5.00 5.00 5.00 5.00 7.48
usha shukla 1.97 1.97 1.97 1.97 1.61
PARTICULARS Dec 2023% Mar 2024% Sep 2024% Mar 2025% Jun 2025%
investors 43.98 43.98 43.98 43.98 49.09
akshay amarnath sharma 1.49 - 1.49 1.49 1.22
bhavesh dhirajlal tanna - - - - 6.61
lenus finvest private lim... - 7.75 7.75 7.75 6.34
mr. niranjan kumar goel 2.98 - 2.98 2.98 2.44
plutus capital management... - - - - 6.34
prakash dhirajlal tanna - 6.72 6.72 6.72 5.50
sanjay dhansukhlal shah 1.49 1.49 1.49 1.49 1.22
vaibhaviben nitinkumar ak... - 1.03 1.03 1.03 -
akshay amarnath sharma . - 1.49 - - -
niranjan kumar goel - 2.98 - - -
pankaj keshav torne 1.82 1.82 - - -
lenus finvest pvt. ltd 7.75 - - - -
prakash dhirajlal tanna 6.72 - - - -
vaibhaviben nitinkumarakh... 1.03 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
Presentation FY2024

Ganga Pharma. Stock Price Analysis and Quick Research Report. Is Ganga Pharma. an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Ganga Pharma.. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Ganga Pharma. has a PE ratio of 110.689916603488 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Ganga Pharma. has ROA of 0.5606% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Ganga Pharma. has a Current ratio of 4.8101.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Ganga Pharma. has a ROE of 0.7847%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Ganga Pharma. has a Debt to Equity ratio of 0.2112 which means that the company has low proportion of debt in its capital.

  • Sales growth: Ganga Pharma. has reported revenue growth of 5.7782% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Ganga Pharma. for the current financial year is 2.10850518883667%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Ganga Pharma. is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Ganga Pharma. is Rs 0.1319. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Ganga Pharma. in Ticker for free. Also, one can get the intrinsic value of Ganga Pharma. by using Valuation Calculators, which are available with a Finology ONE subscription. 

Ganga Pharma. FAQs

Q1. What is Ganga Pharma. share price today?
Ans: The current share price of Ganga Pharma. is Rs 14.6.

Q2. What is the market capitalisation of Ganga Pharma.?
Ans: Ganga Pharma. has a market capitalisation of Rs 8.63079 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Ganga Pharma.?
Ans: The PE ratio of Ganga Pharma. is 110.689916603488 and the P/B ratio of Ganga Pharma. is 1.08750707624467, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Ganga Pharma. share?
Ans: The 52-week high share price of Ganga Pharma. is Rs 19.2, and the 52-week low share price of Ganga Pharma. is Rs 9.25.

Q5. Does Ganga Pharma. pay dividends?
Ans: Currently, Ganga Pharma. does not pay dividends. Dividend yield of Ganga Pharma. is around 0%.

Q6. What are the face value and book value of Ganga Pharma. shares?
Ans: The face value of Ganga Pharma. shares is Rs 10, while the book value per share of Ganga Pharma. is around Rs 13.4252. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Ganga Pharma.?
Ans: Ganga Pharma. has a total debt of Rs 1.35801 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Ganga Pharma.?
Ans: The ROE of Ganga Pharma. is 0.7847% and ROCE of Ganga Pharma. is 3.1607%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Ganga Pharma. a good buy for the long term?
Ans: The Ganga Pharma. long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Ganga Pharma. undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Ganga Pharma. appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Ganga Pharma.’s financials?
Ans: You can review Ganga Pharma.’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Ganga Pharma.
X